Bavarian Nordic (OTCMKTS:BVNRY) Posts Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) posted its quarterly earnings results on Friday. The company reported $0.28 earnings per share for the quarter, Zacks reports. The company had revenue of $277.86 million during the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%.

Bavarian Nordic Stock Performance

Shares of OTCMKTS BVNRY traded down $0.13 during trading hours on Friday, hitting $11.68. The stock had a trading volume of 326 shares, compared to its average volume of 2,944. The firm’s 50-day moving average price is $11.49 and its two-hundred day moving average price is $10.21. Bavarian Nordic has a 52 week low of $8.67 and a 52 week high of $12.72. The company has a market capitalization of $2.78 billion, a P/E ratio of 11.80 and a beta of 1.33.

About Bavarian Nordic

Bavarian Nordic is a Danish biotechnology company that develops, manufactures and markets vaccines for infectious diseases and cancer immunotherapy. Founded in 1994, the company is based in Denmark and serves markets in Europe, North America and other regions. Its best-known vaccine is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, for protection against smallpox and mpox. Bavarian Nordic also offers vaccines for diseases including rabies, tick-borne encephalitis, typhoid fever and cholera.